Evidence snapshot: The strongest human evidence comes from a 2-year randomized controlled trial in 65 healthy older adults (Nass et al., 2008, Annals of Internal Medicine) showing sustained GH/IGF-1 increases and preserved fat-free mass, plus an earlier short-term human polysomnography study on sleep (Copinschi et al., 1997, Neuroendocrinology, PMID 9349662)
A person administering DSIP at bedtime and attributing their 3 a.m
[56] Serum haptocorrin binds 80-90% of circulating B 12 , rendering it unavailable for cellular delivery by transcobalamin II
This synthetic sequence has become a focus in peptide research
long-term safety data is absent
There is a slight decrease in the levels of monoamine metabolites such as homovanillic acid (the major catecholamine metabolite) and 5-hydroxyindoleacetic acid (5-hydroxytryptamine metabolite) [117]